There has been a lot of buzz going around about the Crispr-Cas9 gene-editing technology
But what it is? and what impact could it have on drug development, innovation and new treatments?
What it is?
A fascinating short video created by the McGovern Institute for Brain Research at MIT explains the key characteristics of the technology.
Why is it so exciting?
A Wall Street Journal article reveals what this technology could allow regarding the development of potential new treatments and why it is so exciting.
This new technology will enable the “editing” of defective genes and their replacement by healthy (or normal) genes. Pharmaceutical companies are just starting to explore how to use it as drug discovery would probably be revolutionized. Diseases like cancer, cystic fibrosis,… caused by a mutated gene will eventually find a solution.
Another key advantage is the ease of use. Unless other technologies, Crispr-Cas9 gene-editing technology is much easier to handle than prior methods.
Is it already used?
Yes, it is selected to create genetically engineered research animals for the time being but there is more to come…
Is it dangerous?
It could be, if it is not used correctly and ethically. In April 2015, Chinese scientists used this method to manipulate the DNA of human embryos. This raised fears that it could be used to tune babies up before birth. Manipulating life has to be ethically monitored in order to protect life.
What are the technical hurdles to overcome before creating a drug treatment based on this technology?
Today we do not know how to deliver a drug that could target the right DNA in the right cells. Inactivated viruses or nanoparticles could lead be used as potential carriers.
Overcoming drug delivery hurdles, perfecting the technology, translating it into drugs able to cure genetic disorders will be a fantastic improvement in health sciences. It will bring hope to many patients suffering from these diseases without any cure today.
As the technology is very promising, scientists and universities are currently fighting on the legal battlefield to know who will be the owner of the patents and who will make money from the technology and its application. More details
Biotechnology: At the heart of gene edits in human embryos – Nature – August 2017
Redesigning Life: How Genome Editing Will Transform the World – London School of Economics Book Review – September 2016
Beyond CRISPR: A guide to the many other ways to edit a genome – Nature – August 2016
Federal panel approves first test of CRISPR editing in humans – Washington Post – June 2016
Riding The Gene Editing Wave: Reflections On CRISPR/Cas9’s Impressive Trajectory – LifeSciVC – May 2016
Scientists solve CRISPR’s “Energizer bunny” problem – STAT – April 2016
CRISP biotech Intellia strikes licensing deal with Regeneron, readies for IPO – BioPharmaDive – April 2016
Bill Gates, together with other well-known investors, recently invested in Editas Medicine as part of CRISP-Cas9 frenzy.
Medical specialists urge more debate on gene-editing technology – Reuters – September 2015
CRISPR player Intellia looks IPO-ready after $70M round – FierceBiotech – September 2015
Editing humanity – The Economist – August 2015
Eight Things You Might Not Have Known Until Editas Filed Its S-1 – Xconomy – January 2016
Historic CRISPR Patent Fight Primed To Become Head-To-Head Battle – Xconomy – January 2016